Are There Gender Differences in Anti-HIV Drug Efficacy?
New Rochelle, NY, August 9, 2012 - Women comprise nearly half of the HIV-infected population worldwide,
but these 15.5 million women tend to be under-represented in clinical trials of anti-HIV drug therapies. The U.S. Food and Drug
Administration (FDA) has created a database from 40 clinical studies to assess gender differences in the efficacy of
antiretroviral treatments. The results of this study are presented in an article in AIDS Patient Care and STDs,
a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The
article is available free on the AIDS Patient Care and STDs website.
Guoxing Soon and coauthors from the FDA and University of Texas Southwestern Medical Center, Dallas, TX,
found that women represented only about 20% of the subjects in randomized clinical trials submitted to the FDA between 2000 and 2008.
The article " Meta-Analysis of Gender
Differences in Efficacy Outcomes for HIV-Positive Subjects in Randomized Controlled Clinical Trials of Antiretroviral
Therapy (2000-2008) " compares the effectiveness of anti-HIV drug regimens reported for women versus men overall
and among various subgroups.
The authors found no statistically or clinical significant differences between women and men in outcomes with regard to
viral load after 48 weeks. However, they did report significant gender differences favoring males based on subgroup analyses.
"This is a critical area of research in terms of developing new HIV therapies," says Editor-in-Chief Jeffrey Laurence, MD,
Director of the Laboratory for AIDS Virus Research at Weill Medical College of Cornell University, New York, NY. "Mounting evidence
indicates that metabolism of certain drugs varies in men vs. women, and side effects that interfere with adherence to these
medications may also be manifest differently."
About the Journal
AIDS Patient Care and STDs is the leading journal for clinicians, enabling
them to keep pace with the latest developments in this evolving field. Published monthly in print and online, the Journal spans the
full spectrum of adult and pediatric HIV disease, diagnosis, treatment, prevention, and education. Tables of content and a sample
issue may be viewed on the AIDS Patient Care and STDs website.
About the Publisher
Mary Ann Liebert, Inc., publishers is a privately held, fully integrated media
company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research,
including AIDS Research and Human Retroviruses , Journal of Palliative Medicine , and Viral Immunology . Its biotechnology
trade magazine, Genetic Engineering & Biotechnology News (GEN), was the first in its field and is today the
industry's most widely read publication worldwide. A complete list of the firm's 70 journals and books is
available on the Mary Ann Liebert, Inc., publishers website.
Contact: Vicki Cohn, (914) 740-2156, email@example.com
"Reproduced with permission - Mary Ann Liebert, Inc., publishers"
Mary Ann Liebert, Inc., publishers
For more HIV and AIDS News visit...
Positively Positive - Living with HIV/AIDS: